{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Merkel+Cell+Carcinoma",
    "query": {
      "condition": "Recurrent Merkel Cell Carcinoma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Merkel+Cell+Carcinoma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T00:11:31.233Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03435640",
      "title": "REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "NKTR-262",
          "type": "DRUG"
        },
        {
          "name": "bempegaldesleukin",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-03-15",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Tampa, Florida + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03435640"
    },
    {
      "nct_id": "NCT02978625",
      "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Negative",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Apocrine Carcinoma",
        "Carcinoma Arising From Cylindroma",
        "Carcinoma Arising From Spiradenoma",
        "Digital Papillary Adenocarcinoma",
        "Endocrine Mucin-Producing Sweat Gland Carcinoma",
        "Extramammary Paget Disease",
        "Extraocular Sebaceous Carcinoma",
        "Hidradenocarcinoma",
        "Malignant Sweat Gland Neoplasm",
        "Merkel Cell Carcinoma",
        "Microcystic Adnexal Carcinoma",
        "NK-Cell Lymphoma, Unclassifiable",
        "Papillary Adenocarcinoma",
        "Porocarcinoma",
        "Primary Cutaneous Mucinous Carcinoma",
        "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Anaplastic Large Cell Lymphoma",
        "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
        "Refractory Merkel Cell Carcinoma",
        "Refractory Mycosis Fungoides",
        "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",
        "Refractory Skin Squamous Cell Carcinoma",
        "Refractory T-Cell Non-Hodgkin Lymphoma",
        "Sezary Syndrome",
        "Signet Ring Cell Adenocarcinoma",
        "Skin Adenoid Cystic Carcinoma",
        "Skin Adnexal Carcinoma",
        "Skin Basal Cell Carcinoma",
        "Skin Basosquamous Cell Carcinoma",
        "Skin Keratoacanthoma",
        "Skin Squamous Cell Carcinoma",
        "Squamoid Eccrine Ductal Carcinoma",
        "Squamous Cell Carcinoma of Unknown Primary",
        "Sweat Gland Carcinoma",
        "Trichilemmal Carcinoma",
        "Vulvar Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Mammography",
          "type": "PROCEDURE"
        },
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2017-09-27",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 36,
      "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978625"
    },
    {
      "nct_id": "NCT04187872",
      "title": "LITT and Pembrolizumab in Recurrent Brain Metastasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Non-small Cell Lung Carcinoma (NSCLC)",
        "Renal Cell Carcinoma (RCC)",
        "Small-cell Lung Cancer",
        "Head and Neck Squamous Cell Cancer",
        "Classical Hodgkin Lymphoma",
        "Primary Mediastinal Large B-Cell Lymphoma",
        "Urothelial Carcinoma",
        "Microsatellite Instability-High Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Merkel Cell Carcinoma",
        "Brain Metastases, Adult"
      ],
      "interventions": [
        {
          "name": "LITT + Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2020-01-10",
      "completion_date": "2023-12-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-27",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Jacksonville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04187872"
    },
    {
      "nct_id": "NCT00003549",
      "title": "S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Carcinoma of the Skin"
      ],
      "interventions": [
        {
          "name": "CMF regimen",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "1998-10",
      "completion_date": "2003-01",
      "has_results": false,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 84,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003549"
    },
    {
      "nct_id": "NCT00003514",
      "title": "Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma",
        "Islet Cell Carcinoma",
        "Neuroendocrine Carcinoma",
        "Pituitary Tumor"
      ],
      "interventions": [
        {
          "name": "antineoplaston A10",
          "type": "DRUG"
        },
        {
          "name": "antineoplaston AS2-1",
          "type": "DRUG"
        },
        {
          "name": "alternative product therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biological therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biologically based therapies",
          "type": "PROCEDURE"
        },
        {
          "name": "cancer prevention intervention",
          "type": "PROCEDURE"
        },
        {
          "name": "complementary and alternative therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "differentiation therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Burzynski Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003514"
    },
    {
      "nct_id": "NCT02514824",
      "title": "MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "MLN0128",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-10",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-12-29",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02514824"
    },
    {
      "nct_id": "NCT00655655",
      "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrinoma",
        "Glucagonoma",
        "Insulinoma",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic Pheochromocytoma",
        "Pancreatic Polypeptide Tumor",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Islet Cell Carcinoma",
        "Recurrent Melanoma",
        "Recurrent Neuroendocrine Carcinoma of the Skin",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Pheochromocytoma",
        "Recurrent Renal Cell Cancer",
        "Somatostatinoma",
        "Stage III Neuroendocrine Carcinoma of the Skin",
        "Stage IV Melanoma",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Renal Cell Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "vatalanib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "dynamic contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "ultrasound imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2004-12",
      "completion_date": "2018-01-11",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655655"
    },
    {
      "nct_id": "NCT01758458",
      "title": "Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Merkel Cell Carcinoma",
        "Stage IV Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Recombinant Interferon Beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2013-02",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2017-04-19",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01758458"
    },
    {
      "nct_id": "NCT01155258",
      "title": "Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Extensive Stage Small Cell Lung Cancer",
        "Hereditary Paraganglioma",
        "Male Breast Cancer",
        "Malignant Paraganglioma",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic Pheochromocytoma",
        "Pancreatic Polypeptide Tumor",
        "Recurrent Breast Cancer",
        "Recurrent Cervical Cancer",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Islet Cell Carcinoma",
        "Recurrent Neuroendocrine Carcinoma of the Skin",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Pheochromocytoma",
        "Recurrent Prostate Cancer",
        "Recurrent Renal Cell Cancer",
        "Recurrent Small Cell Lung Cancer",
        "Recurrent Uterine Sarcoma",
        "Regional Gastrointestinal Carcinoid Tumor",
        "Regional Pheochromocytoma",
        "Stage III Cervical Cancer",
        "Stage III Endometrial Carcinoma",
        "Stage III Neuroendocrine Carcinoma of the Skin",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Ovarian Germ Cell Tumor",
        "Stage III Prostate Cancer",
        "Stage III Renal Cell Cancer",
        "Stage III Uterine Sarcoma",
        "Stage IIIA Breast Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer",
        "Stage IV Endometrial Carcinoma",
        "Stage IV Neuroendocrine Carcinoma of the Skin",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Ovarian Germ Cell Tumor",
        "Stage IV Prostate Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Uterine Sarcoma",
        "Stage IVA Cervical Cancer",
        "Stage IVB Cervical Cancer",
        "Thyroid Gland Medullary Carcinoma"
      ],
      "interventions": [
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine ditartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2010-06",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-13",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01155258"
    },
    {
      "nct_id": "NCT00068783",
      "title": "S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Neuroendocrine Carcinoma of the Skin",
        "Stage II Neuroendocrine Carcinoma of the Skin",
        "Stage III Neuroendocrine Carcinoma of the Skin"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-05-22T00:11:31.233Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00068783"
    }
  ]
}